Lantern Pharma Inc., a pharmaceutical company traded under the ticker symbol LTRN, aims to transform the process of cancer drug development through the application of artificial intelligence (AI), machine learning, and genomics. This clinical-stage biopharmaceutical company is headquartered in Dallas, Texas and houses its AI platform and drug development facilities there.
Lantern Pharma develops its drugs through the company’s proprietary artificial intelligence platform, known as the RADR® platform. A vital part of Lantern's business model, RADR®, uses machine learning algorithms to predict the likelihood of success for certain cancer drugs. This approach allows the company to increase the speed and efficiency of cancer drug development, lowering costs and potentially improving patient outcomes. The RADR® platform currently helps guide and accelerate the development of the company’s drug pipeline, which includes three drugs in different stages of clinical development targeting unique and significant unmet needs in oncology.
One of the most promising drugs in Lantern Pharma's pipeline, LP-100, is an investigational treatment for prostate cancer that has shown potential in early clinical trials. The second drug, LP-300, is a potential treatment for non-small cell lung cancer, currently in Phase 2 development phase. The third one, LP-184, is a potential treatment for solid tumors that are responsive to the drug based on genetic markers, currently in the pre-clinical trial phase.
Since its inception in 2013, Lantern Pharma has been working diligently to revolutionize the traditional approach to cancer drug development. The use of AI to identify potential drug candidates sharply contrasts with the typical trial and error method used in pharmaceuticals. As a result, Lantern Pharma has become a beacon of hope due to its approach to accelerating the development of cancer treatments and the potential to bring these therapies to patients faster.
Although the company remains in the clinical phase for its various candidate compounds, it has gained attention from investors and the medical community for its innovative use of technology. With its pioneering use of AI, and a focus on genomic data, Lantern Pharma represents a cutting-edge trend in pharmaceutical development.
In conclusion, Lantern Pharma Inc. is dedicated to transforming cancer drug development using AI and genomics to rapidly identify and develop targeted therapies for patients suffering from a variety of malignancies. Its RADR® platform could significantly reduce the lead times and costs associated with traditional drug development, potentially leading to faster, more effective treatments for patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Lantern Pharma Inc. (LTRN) has released a slide deck discussing its Open-Medicine AI platform. The presentation outlines the platform's roadmap, business model, and its value proposition for the development of therapeutic treatments. This information was published in conjunction with an event.
New to The Street will broadcast interviews with executives from BioVie, Acurx Pharmaceuticals, Lantern Pharma, and SafeSpace Global tonight at 6:30 PM ET. The program, distributed across the US, Latin America, and MENA, will cover topics including Long COVID treatments, new antibiotics, AI in oncology drug development, and AI-powered security platforms. The co-founder and CEO of New to The Street, Vince Caruso, highlighted the platform's reach for innovative companies to communicate with investors and the public.
New to The Street is broadcasting interviews tonight at 6:30 PM ET featuring executives from BioVie, Acurx Pharmaceuticals, Lantern Pharma, and SafeSpace Global. The program will cover topics including Long COVID clinical results, new antibiotic development, AI in oncology research, and AI-powered security platforms. It will air across Bloomberg Television's U.S., Latin America, and MENA markets.
Lantern Pharma reported significant progress in its AI-driven drug development, highlighted by the establishment of Open Medicine AI as a separate entity to commercialize its AI models. The company achieved a 25% reduction in operating expenses year-over-year while advancing multiple clinical programs, including promising results for LP300 in non-small cell lung cancer and regulatory clearances for LP184 trials. Open Medicine AI, wholly owned by Lantern Pharma, aims to raise independent capital and pursue a separate listing, leveraging the growing AI market in drug discovery.